GCC 2546- Motion Management

NCT07398209 | Not Yet Recruiting DMC

• 1 other identifier: HP-00114565
• Study Type: interventional
• Target: 44
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is to assess a real time motion tracking of lung tumors and important organs next to the tumor while breathing during a participant's radiation treatment. This will be assessed through a four-dimensional magnetic resonance imaging (MRI) scan before starting your radiation treatment and x-ray fluoroscopy images that are taken during radiation

Conditions

Lung Cancer (NSCLC); Radiation

Outcome Measures

Primary Outcomes (1)

• To investigate if time-resolved, multicycle volumetric motion modeling and monitoring gives improved spatiotemporal localization of the tumor target and OARs compared to current standard-of-care 4DCT-based motion modeling and monitoring

  3 years

Study Arms (1)

Imaging

EXPERIMENTAL

At baseline, patients will receive a 4D CT Simulation (standard of care) along with a 4D MRI with surface monitoring (research). During their radiation treatment, they will receive additional fluoroscopy imaging and surface monitoring.

Other: MRI

Interventions

MRI OTHER

Baseline 4D CT Simulation and 4S MRI with surface monitoring through EndoScout vest, followed by fluoroscopy and additional surface monitoring while undergoing daily radiation.

Also known as: Fluoroscopy, Surface Monitoring

Imaging

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Adult (≥18 years) patients (both sexes) with histologically diagnosed Stage II-IIIb NSCLC
• Patients to be treated with definitive external beam photon radiotherapy with or without systemic therapy (e.g., chemotherapy, immunotherapy).
• No restrictions on number radiotherapy fractions, or location/number of lesions
• ECOG performance status ≤ 3
• Ability to undergo MRI scans
• Patient has signed informed consent document and agreed to study procedures

You may not qualify if:

• Pre-existing contraindications for MRI, such as any MRI-conditional or MRI-unsafe foreign objects within the body, non-removable ear cochlear or eye implant, aneurysm clip, cardiac pacemaker/wires, internal defibrillator, tissue expander, recent stent placement, penile prosthesis, medication patch, artificial limb, pregnancy, and claustrophobia
• Women who are pregnant or trying to get pregnant (self-reported)
• Pain in supine position or inability to raise arm above head in supine position

Sponsors & Collaborators

• University of Maryland, Baltimore: lead

Study Sites (1)

University of Maryland Greenebaum Cancer Center

Baltimore, Maryland, 21201, United States

Location

MeSH Terms

Conditions

Lung Neoplasms; Carcinoma, Non-Small-Cell Lung

Condition Hierarchy (Ancestors)

Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Diseases; Carcinoma, Bronchogenic; Bronchial Neoplasms

Study Officials

• Amit Sawant, PhD

  University of Maryland, Baltimore

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Amit Sawant, PhD

CONTACT

410-328-6080; asawant@som.umaryland.edu

Caitlin Eggleston, MPH

CONTACT

410-369-5351; caitlineggleston@umm.edu

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: SUPPORTIVE CARE
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator

Study Record Dates

• First Submitted: February 2, 2026
• First Posted: February 9, 2026
• Study Start: April 1, 2026
• Primary Completion (Estimated): April 1, 2028
• Study Completion (Estimated): April 1, 2029
• Last Updated: February 9, 2026

Record last verified: 2026-02

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)